Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.
Saved in:
| Title: | Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. |
|---|---|
| Authors: | Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dayyani F; Chao Family Comprehensive Cancer Center, University of California at Irvine, Orange, CA, USA., Sommerhalder D; NEXT Oncology, San Antonio, TX, USA., Vandross AL; NEXT Oncology, Austin, TX, USA., Pelster MS; Sarah Cannon Research Institute, Nashville, TN, USA., Henry JT; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA., Perez CA; Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, USA., Chakraborty A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Baysal MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chandhasin C; Tachyon Therapeutics Inc., San Francisco, CA, USA., Dai Y; Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, USA., Tu S; Tachyon Therapeutics Inc., San Francisco, CA, USA., King I; Tachyon Therapeutics Inc., San Francisco, CA, USA., Perabo F; Tachyon Therapeutics Inc., San Francisco, CA, USA. |
| Source: | The oncologist [Oncologist] 2025 Jul 04; Vol. 30 (7). |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyaf169 |
